204 related articles for article (PubMed ID: 9150467)
1. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
[TBL] [Abstract][Full Text] [Related]
2. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts.
Owen WF; Hou FF; Stuart RO; Kay J; Boyce J; Chertow GM; Schmidt AM
Kidney Int; 1998 May; 53(5):1365-73. PubMed ID: 9573554
[TBL] [Abstract][Full Text] [Related]
3. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
[TBL] [Abstract][Full Text] [Related]
4. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
5. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.
Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y
Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842
[TBL] [Abstract][Full Text] [Related]
6. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
[TBL] [Abstract][Full Text] [Related]
7. Extraskeletal problems and amyloid.
Drüeke TB
Kidney Int Suppl; 1999 Dec; 73():S89-93. PubMed ID: 10633472
[TBL] [Abstract][Full Text] [Related]
8. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
[TBL] [Abstract][Full Text] [Related]
9. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.
Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877
[TBL] [Abstract][Full Text] [Related]
10. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
11. Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis.
Miyata T; Wada Y; Maeda K
Contrib Nephrol; 1995; 112():52-64. PubMed ID: 7554993
[No Abstract] [Full Text] [Related]
12. Pathogenesis of dialysis-related amyloidosis.
Miyata T; Maeda K
Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):493-7. PubMed ID: 8591057
[TBL] [Abstract][Full Text] [Related]
13. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T
J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
Miyata T; Inagi R; Kurokawa K
Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
[TBL] [Abstract][Full Text] [Related]
15. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
Miyata T; Maeda K
Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015
[No Abstract] [Full Text] [Related]
16. Detection and quantitation of beta-2-microglobulin glycosylated end products in human serum by matrix-assisted laser desorption/ionization mass spectrometry.
Tang X; Sadeghi M; Olumee Z; Vertes A; Braatz JA; McIlwain LK; Dreifuss PA
Anal Chem; 1996 Nov; 68(21):3740-5. PubMed ID: 8914482
[TBL] [Abstract][Full Text] [Related]
17. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G
J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976
[TBL] [Abstract][Full Text] [Related]
18. Beta2-microglobulin and renal bone disease.
Wada T; Miyata T; Sakai H; Kurokawa K
Perit Dial Int; 1999; 19 Suppl 2():S413-6. PubMed ID: 10406556
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis.
Miyata T; Sprague SM
Nephrol Dial Transplant; 1996; 11 Suppl 3():86-90. PubMed ID: 8840320
[No Abstract] [Full Text] [Related]
20. Beta-2 microglobulin in ESRD: an in-depth review.
Winchester JF; Salsberg JA; Levin NW
Adv Ren Replace Ther; 2003 Oct; 10(4):279-309. PubMed ID: 14681859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
